Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Authors:
  • KRKlaus F. Rabe
    Klaus F. Rabe
  • PNParameswaran Nair
    Parameswaran Nair
  • JMJorge F. Maspero
    Jorge F. Maspero
  • MCMario Castro
    Mario Castro
  • LSLawrence Sher
    Lawrence Sher
  • HZHongjie Zhu
    Hongjie Zhu
  • JHJennifer D. Hamilton
    Jennifer D. Hamilton
  • BSBrian N. Swanson
    Brian N. Swanson
  • JCJingdong Chao
    Jingdong Chao
  • HSHeribert Staudinger
    Heribert Staudinger

Abstract
Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining asthma control is unknown.
Funding Information
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi

This publication has 24 references indexed in Scilit: